Cargando…
Dosing interval adjustment of denosumab for the treatment of giant cell tumor of the sphenoid bone: A case report
BACKGROUND: In the treatment of giant cell tumor of bone (GCTB), the efficacy and safety of denosumab, a receptor activator nuclear factor κ-B ligand inhibitor, has previously been demonstrated, especially for unresectable tumors. One of the current issues in denosumab treatment for unresectable GCT...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Scientific Scholar
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771493/ https://www.ncbi.nlm.nih.gov/pubmed/33408904 http://dx.doi.org/10.25259/SNI_439_2020 |